Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.33 |
| ▸ | CNR2 | P34972 | 3/20 | 0.33 |
| ▸ | CNR1 | P21554 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1407021 | 0.85 | HSD11B1 (0.54) | HSD11B1CNR2CNR1 | |
| SCHEMBL20108780 | 0.80 | POLB (0.45) | KDM4EHSD17B10CNR2CNR1ALDH1A1 | |
| SCHEMBL12809751 | 0.79 | HSD11B1 (0.39) | HSD11B1KDM4EHSD17B10HCRTR1ALDH1A1 | |
| SCHEMBL12809588 | 0.79 | HSD11B1 (0.39) | HSD11B1KDM4EHSD17B10HCRTR1ALDH1A1 | |
| SCHEMBL13294003 | 0.77 | HSD11B1 (0.59) | HSD11B1 | |
| SCHEMBL4720680 | 0.77 | HSD11B1 (0.59) | HSD11B1 | |
| SCHEMBL13294019 | 0.75 | HSD11B1 (0.44) | HSD11B1 | |
| SCHEMBL3291161 | 0.74 | LMNA (0.41) | KDM4EEGLN1HCRTR1NPC1RAB9A | |
| SCHEMBL13310658 | 0.74 | HCRTR1 (0.34) | HSD11B1EGLN1HCRTR1 | |
| SCHEMBL14413253 | 0.73 | HSD11B1 (0.43) | HSD11B1HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10894054-B2 | FXR agonist compositions for combination therapy | INTERCEPT PHARMACEUTICALS, INC. (US) | 2021-01-19 | — | — | US | disclosed |
| US-20180117065-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | INTERCEPT PHARMACEUTICALS, INC. | 2018-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894054-B2 | FXR agonist compositions for combination therapy | GPR119, FXR1, NR1H4 | HSD11B1 241/4885KDM4E 4672/4885HSD17B10 337/4885 |
| US-20180117065-A1 | PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY | GPR119, FABP1, SLC10A1 | HSD11B1 214/4885KDM4E 4738/4885HSD17B10 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.